Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CTRC | Q99895 | 5/20 | 0.41 |
| ▸ | CMA1 | P23946 | 4/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239360 | 0.78 | CMA1 (0.53) | KDM4ECTRCCMA1ELANE | |
| SCHEMBL6803058 | 0.78 | NPC1 (0.41) | TSHRAKR1B10KDM4EALDH1A1HPGD | |
| SCHEMBL6804111 | 0.77 | CMA1 (0.53) | KDM4ECTRCCMA1ELANE | |
| Hydrochloric Acid SCHEMBL6805327 | 0.77 | CMA1 (0.53) | KDM4ECTRCCMA1ELANE | |
| SCHEMBL2801401 | 0.77 | APEX1 (0.44) | TSHRKDM4EALDH1A1HPGDAPEX1 | |
| SCHEMBL6800734 | 0.74 | GAA (0.40) | AKR1B10KDM4EALDH1A1HPGDAPEX1 | |
| SCHEMBL6804164 | 0.74 | CMA1 (0.48) | CTRCCMA1ELANE | |
| SCHEMBL6805699 | 0.71 | CMA1 (0.52) | CTRCCMA1 | |
| SCHEMBL30765971 | 0.71 | POLB (0.38) | KDM4EALDH1A1HPGDAPEX1CTRC | |
| SCHEMBL11556278 | 0.71 | TSHR (0.47) | TSHRAKR1B10KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | DPYD, NUDT1, UMPS | TSHR 3337/4885AKR1B10 497/4885KDM4E 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.